Genmab and AbbVie demonstrate significant clinical improvement in DLBCL patients using Epcoritamab combined with R-CHOP
Executive summary: Genmab and AbbVie announced that the combination treatment of Epcoritamab and R-CHOP showed a statistically significant improvement in progression-free survival for patients diagnosed with newly diagnosed Diffuse Large B-Cell Lymphoma. Positive clinical outcomes in DLBCL can lead to changes in treatment protocols, potential regulatory approvals, and expanded market share for the companies involved.
Who is involved: Genmab, AbbVie
Likely next (inference): Submission of clinical data to regulatory bodies such as the FDA or EMA for potential indication expansion.
Genmab and AbbVie have reported positive clinical data showing that the combination of Epcoritamab and R-CHOP significantly improves progression-free survival in patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). This development represents a potential shift in the standard of care for this specific oncology indication. The success of this combination therapy reinforces the collaborative R&D efforts between the two biopharma companies in the hematologic malignancy space.
What's next — scenarios
Inference: scenarios and probabilities are Beyond's assessment, not reported fact.
Base: Regulatory approval for new indication (60%)
Expansion of Epcoritamab's market reach into the newly diagnosed DLBCL segment.
- FDA/EMA filing based on this data
- Positive advisory committee feedback
Upside: Rapid adoption as standard of care (25%)
Significant revenue acceleration for both Genmab and AbbVie in the oncology portfolio.
- Comparative superiority shown against current gold standards in subsequent real-world data
Downside: Regulatory delay or safety concerns (15%)
Delayed commercialization and potential impact on oncology stock valuations.
- Emergence of unexpected adverse events in expanded patient cohorts
What to watch
- Upcoming regulatory filing timelines for Epcoritamab in DLBCL
- Detailed safety profile disclosures from the clinical study
Timeline
- — Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (GlobeNewswire)
- — U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease (PR Newswire)
- — AbbVie Stock Just Posted a 74% Response Rate in Myeloma. Here’s What It Means for the Stock in 2026 (Yahoo Finance)
Analysis — what this means
Sectors affected
- Oncology therapeutics
- Biopharmaceutical manufacturing
- Hematology healthcare providers
Regulatory implications
- Requirement for expanded clinical data sets for new indication approval
Historical parallels
- AbbVie's recent FDA approval for JUVMO (tavapadon) in Parkinson's disease (Sept 2026)
Key entities
Sources
- Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma — GlobeNewswire
- AbbVie Stock Just Posted a 74% Response Rate in Myeloma. Here’s What It Means for the Stock in 2026 — Yahoo Finance
- U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease — PR Newswire
Related cases
- AbbVie's Phase 2 trial shows its experimental drug zumilokibart significantly improves eczema symptoms versus placebo, advancing a potential new atopic dermatitis therapy
- Pharma deal volume jumps 70% to €343.5bn Jan‑Jul 2026, led by Lilly, BMS, AbbVie and GSK
- AbbVie seeks EMA approval for subcutaneous risankizumab induction in Crohn’s disease, expanding its immunology portfolio
- AbbVie’s neuroscience division is projected to generate $12.7 billion in sales this year, marking a key shift away from its Humira‑centric model
- Patent expirations on blockbuster drugs threaten $440 billion in pharma revenues, with Merck-MSD and AbbVie most exposed
- Healthcare stocks become a safe haven as investors exit tech